Home » Topics » BioWorld Science

BioWorld Science
RSS

BeiGene initiates two global phase III studies of tislelizumab

Dec. 18, 2018

Topline results presented from phase I study of XCUR-17 in chronic plaque psoriasis

Dec. 18, 2018

Keytruda approved in Europe as adjuvant therapy for adults with resected stage III melanoma

Dec. 18, 2018

Kineta and Pfizer collaborate to develop RIG-I agonist immunotherapies for cancer

Dec. 18, 2018

Araxes Pharma identifies new mutant KRAS inhibitors

Dec. 18, 2018

Taisho Pharmaceutical discloses bacterial LpxC inhibitors

Dec. 18, 2018

Chengdu Euthare Therapeutics synthesizes CDK4 and CDK6 inhibitors

Dec. 18, 2018

Abbisko Therapeutics divulges new CSF-1R inhibitors

Dec. 18, 2018

Cancer Research Technology patents BCL-6 inhibitors

Dec. 18, 2018

Reduced RNA editing links different forms of autism

Dec. 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Other news to note for July 27, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbvie, Genmab, Merck, Par, Thyora.